FLII and Ewing sarcoma: Targeted therapy against this fusion protein or its products may inhibit growth of Ewing’s sarcoma cells.55 However, efficient delivery of EWS-FLI antisense oligonucleotide to malignant cells remains a barrier to therapeutic application of these agents.